1. Home
  2. Stocks
  3. Kilitch Share Price

Kilitch Drugs(I) Share Price

Pharmaceuticals Small Cap

₹312.60 +0.65 (0.21%)

05 Nov, 2024 21:05

SIP TrendupStart SIP in KILITCH

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹310
  • High
  • ₹318
  • 52 Week Low
  • ₹300
  • 52 Week High
  • ₹470
  • Open Price₹315
  • Previous Close₹312
  • Volume3,078

Investment Returns

  • Over 1 Month -6.71%
  • Over 3 Month -15.89%
  • Over 6 Month -11.99%
  • Over 1 Year + 3.58%
SIP Lightning

Smart Investing Starts Here Start SIP with Kilitch Drugs(I) for Steady Growth!

Kilitch Drugs(I) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 39.9
  • PEG Ratio
  • 5.4
  • Market Cap Cr
  • 503
  • P/B Ratio
  • 2.9
  • Average True Range
  • 16.53
  • EPS
  • 10.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -8.97
  • RSI
  • 41.39
  • MFI
  • 52.46

Kilitch Drugs(I) Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations33.4239.1429.7731.5731.12
Total Income From Operations33.4239.1429.7731.5731.12
P/L Before Interest, Excpt. Items & Tax6.085.707.126.365.96
P/L Before Exceptional Items & Tax5.595.266.585.935.58
P/L After Tax from Ordinary Activities4.053.645.504.244.19
Net Profit/Loss For the Period4.053.645.504.244.19
IndicatorMar 24Mar 23
Revenue From Operations [Gross]130.83117.04
Revenue From Operations [Net]130.83117.04
Total Operating Revenues131.60117.78
Total Revenue137.79122.38
Total Expenses114.43102.93
Profit/Loss Before Tax23.3519.45
Profit/Loss For The Period17.5715.72
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-1.196.10
Net Cash Used In Investing Activity-10.106.24
Net Cash Used in Finance Activity11.403.04
Net Inc/Dec In Cash And Equivalent0.1115.39
Cash And Equivalent End Of Year17.9517.84
IndicatorMar 24Mar 23
Total Share Capital16.0815.58
Total Non-Current Liabilities0.170.07
Total Current Liabilities64.3756.42
Total Capital And Liabilities287.47252.42
Total Non-Current Assets145.98137.65
Total Current Assets141.49114.77
Total Assets287.47252.42
Indicator20242023
EBIT Margin (%)19.1917.34
Return On Capital Employed (%)11.3210.42
Return On Equity (%)7.888.02
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)138.61125.74
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations33.4544.8231.7941.2036.56
Total Income From Operations33.4544.8231.7941.2036.56
P/L Before Interest, Excpt. Items & Tax3.386.624.428.295.95
P/L Before Exceptional Items & Tax1.655.302.826.784.45
P/L After Tax from Ordinary Activities0.113.681.745.093.06
Net Profit/Loss For the Period0.113.681.745.093.06
IndicatorMar 24Mar 23
Revenue From Operations [Gross]153.61138.86
Revenue From Operations [Net]153.61138.86
Total Operating Revenues154.37139.60
Total Revenue158.85142.52
Total Expenses139.50130.50
Profit/Loss Before Tax19.3512.01
Profit/Loss For The Period13.588.28
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-0.152.59
Net Cash Used In Investing Activity-9.547.92
Net Cash Used in Finance Activity8.81-0.72
Net Inc/Dec In Cash And Equivalent-0.889.78
Cash And Equivalent End Of Year18.9619.85
IndicatorMar 24Mar 23
Total Share Capital16.0815.58
Total Non-Current Liabilities0.170.07
Total Current Liabilities64.2268.87
Total Capital And Liabilities240.06219.52
Total Non-Current Assets94.0793.12
Total Current Assets145.99126.40
Total Assets240.06219.52
Indicator20242023
EBIT Margin (%)16.3712.12
Return On Capital Employed (%)14.3711.24
Return On Equity (%)8.286.89
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)109.2396.64

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
₹312.60
+ 0.65 (0.21%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹321.96
  • 50 Day
  • ₹333.55
  • 100 Day
  • ₹339.85
  • 200 Day
  • ₹335.28

Resistance and Support

313.72 Pivot Speed
  • R3 325.68
  • R2 322.07
  • R1 317.33
  • S1 308.98
  • S2 305.37
  • S3 300.63

Is Kilitch Drugs(I) Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs India has an operating revenue of Rs. 151.27 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Kilitch Drugs(I) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Quarterly Results
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results

Kilitch Drugs(I) F&O

Kilitch Drugs(I) Shareholding Pattern

69.23%
0%
0%
25.1%
5.67%
  • NSE Symbol
  • KILITCH
  • BSE Symbol
  • 524500
  • Managing Director
  • Mr. Mukund P Mehta
  • ISIN
  • INE729D01010

Kilitch Drugs(I) FAQs

Kilitch Drugs(I) share price is ₹312 As on 05 November, 2024 | 20:51

The Market Cap of Kilitch Drugs(I) is ₹502.7 Cr As on 05 November, 2024 | 20:51

The P/E ratio of Kilitch Drugs(I) is 39.9 As on 05 November, 2024 | 20:51

The PB ratio of Kilitch Drugs(I) is 2.9 As on 05 November, 2024 | 20:51

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.